neostigmine has been researched along with Tachycardia in 31 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our case suggests that neostigmine, an acetylcholinesterase inhibitor, may warrant further investigation in patients with thyroid storm-induced severe sinus tachycardia." | 8.98 | Use of low-dose neostigmine intravenously in the treatment of thyroid storm-induced severe tachycardia in patient during huge pelvic mass resection: A case report and review of literature. ( Jiang, H; Li, S; Luo, A; Zhang, X; Zhao, Y, 2018) |
| "Compared with neostigmine/glycopyrrolate, incidence of TE sinus bradycardia was significantly lower with sugammadex 2 mg/kg and incidence of TE sinus tachycardia was significantly lower with sugammadex 2 mg/kg and 4 mg/kg." | 5.41 | A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants. ( Blobner, M; Broussard, DM; Herring, WJ; Lin, L; Lombard, JF; Lutkiewicz, J; Mukai, Y; Wang, A; Watkins, M, 2021) |
| " The only existed anticholinergic in Thailand is atropine, which has a more rapid onset than neostigmine resulting in initial tachycardia." | 5.19 | A comparison of the combination of atropine and glycopyrrolate with atropine alone for the reversal of muscle relaxant. ( Ittichaikulthol, W; Komonhirun, R; Piathong, P; Pisitsak, C; Suyawet, R; Wirachpisit, N, 2014) |
| "Our case suggests that neostigmine, an acetylcholinesterase inhibitor, may warrant further investigation in patients with thyroid storm-induced severe sinus tachycardia." | 4.98 | Use of low-dose neostigmine intravenously in the treatment of thyroid storm-induced severe tachycardia in patient during huge pelvic mass resection: A case report and review of literature. ( Jiang, H; Li, S; Luo, A; Zhang, X; Zhao, Y, 2018) |
| "Neuromuscular blockade reversal with neostigmine and glycopyrrolate was associated with an increased incidence of intraoperative tachycardia and bradycardia but not with 30-day postoperative cardiovascular complications." | 3.96 | Effects of Anticholinesterase Reversal Under General Anesthesia on Postoperative Cardiovascular Complications: A Retrospective Cohort Study. ( Deng, H; Eikermann, M; Forman, SA; Houle, TT; Kelly, BJ; Lihn, AL; Nourmahnad, A; Scheffenbichler, FT; Shaydenfish, D; Xu, X, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (70.97) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (9.68) | 29.6817 |
| 2010's | 3 (9.68) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Herring, WJ | 1 |
| Mukai, Y | 1 |
| Wang, A | 1 |
| Lutkiewicz, J | 1 |
| Lombard, JF | 1 |
| Lin, L | 1 |
| Watkins, M | 1 |
| Broussard, DM | 1 |
| Blobner, M | 1 |
| Zhang, X | 1 |
| Jiang, H | 1 |
| Li, S | 1 |
| Luo, A | 1 |
| Zhao, Y | 1 |
| Shaydenfish, D | 1 |
| Scheffenbichler, FT | 1 |
| Kelly, BJ | 1 |
| Lihn, AL | 1 |
| Deng, H | 1 |
| Nourmahnad, A | 1 |
| Xu, X | 1 |
| Houle, TT | 1 |
| Eikermann, M | 1 |
| Forman, SA | 1 |
| Ittichaikulthol, W | 1 |
| Pisitsak, C | 1 |
| Wirachpisit, N | 1 |
| Piathong, P | 1 |
| Suyawet, R | 1 |
| Komonhirun, R | 1 |
| Tribuddharat, S | 1 |
| Sathitkarnmanee, T | 1 |
| Naewthong, P | 1 |
| WALDMAN, S | 1 |
| PELNER, L | 1 |
| Dubost, C | 1 |
| de Saint Maurice, G | 1 |
| Vichard, A | 1 |
| Berbari, H | 1 |
| Lenoir, B | 1 |
| LEVINE, EB | 1 |
| BLUMFIELD, G | 1 |
| PARTILLA, H | 1 |
| LAMVIK, J | 1 |
| YOUNG, D | 1 |
| ZISLIN, BD | 1 |
| FORSHTADT, VM | 1 |
| LYSKOV, PG | 1 |
| TURBINA, NV | 1 |
| GREENWOOD, RJ | 1 |
| FURMAN, RH | 1 |
| GEIGER, AJ | 1 |
| Sawasdiwipachai, P | 1 |
| Laussen, PC | 1 |
| McGowan, FX | 1 |
| Smoot, L | 1 |
| Casta, A | 1 |
| Backman, SB | 1 |
| Nymark, M | 1 |
| Rasmussen, J | 1 |
| Donald, DE | 1 |
| Samueloff, SL | 1 |
| Ferguson, D | 1 |
| Homola, D | 1 |
| Srnova, V | 1 |
| Dreifus, L | 1 |
| Satinsky, JD | 1 |
| Raymond, CW | 1 |
| Robinson, SJ | 1 |
| Andersen, O | 1 |
| Lindberg, J | 1 |
| Modigh, K | 1 |
| Reske-Nielsen, E | 1 |
| Preston, TA | 1 |
| Yates, JD | 1 |
| Brymer, JF | 1 |
| Marriott, HJ | 1 |
| Ramamurthy, S | 1 |
| Shaker, MH | 1 |
| Winnie, AP | 1 |
| Rosner, V | 1 |
| Kepes, ER | 1 |
| Foldes, FF | 1 |
| Fidelle, J | 1 |
| Cloup, M | 1 |
| Nouaille, J | 1 |
| Richmond, DR | 1 |
| Smith, DR | 1 |
| Fekete, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (A[NCT03346057] | Phase 4 | 344 participants (Actual) | Interventional | 2017-12-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
As per the protocol primary analysis, the percentage of participants experiencing an SAE up to 7 days after administration of study intervention was reported. An SAE was an adverse event that: resulted in death; was life threatening; resulted in persistent or significant disability or incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly or birth defect; was an other important medical event, was a cancer; or was associated with an overdose. (NCT03346057)
Timeframe: Up to 7 days
| Intervention | Percentage of Participants (Number) |
|---|---|
| Sugammadex 2 mg/kg | 11.4 |
| Sugammadex 4 mg/kg | 7.5 |
| Sugammadex 16 mg/kg | 10.3 |
| Neostigmine + Glycopyrrolate | 5.9 |
As per the protocol primary analysis, the percentage of participants experiencing an AE up to 7 days after administration of study intervention was reported. An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. (NCT03346057)
Timeframe: Up to 7 days
| Intervention | Percentage of participants (Number) |
|---|---|
| Sugammadex 2 mg/kg | 94.3 |
| Sugammadex 4 mg/kg | 88.8 |
| Sugammadex 16 mg/kg | 92.6 |
| Neostigmine + Glycopyrrolate | 88.2 |
The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events was identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias were defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachycardia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not have been considered an AE, as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration
| Intervention | Percentage of participants (Number) |
|---|---|
| Sugammadex 2 mg/kg | 1.0 |
| Sugammadex 4 mg/kg | 0.0 |
| Sugammadex 16 mg/kg | 1.5 |
| Neostigmine + Glycopyrrolate | 2.0 |
The percentage of participants experiencing treatment-emergent sinus bradycardia events was identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia were defined as a heart rate <60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not have been considered an adverse event (AE), as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration
| Intervention | Percentage of participants (Number) |
|---|---|
| Sugammadex 2 mg/kg | 1.0 |
| Sugammadex 4 mg/kg | 1.9 |
| Sugammadex 16 mg/kg | 7.4 |
| Neostigmine + Glycopyrrolate | 7.8 |
The percentage of participants experiencing treatment-emergent sinus tachycardia events was identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not have been considered an AE, as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration
| Intervention | Percentage of participants (Number) |
|---|---|
| Sugammadex 2 mg/kg | 6.7 |
| Sugammadex 4 mg/kg | 9.3 |
| Sugammadex 16 mg/kg | 8.8 |
| Neostigmine + Glycopyrrolate | 21.6 |
As per the protocol primary analysis, the percentage of participants experiencing an ECI up to 7 days after administration of study intervention was reported. ECIs were a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. A participant could have experienced more than one type of ECI. (NCT03346057)
Timeframe: Up to 7 days
| Intervention | Percentage of Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| With one or more ECIs | Adjudicated Hypersensitivity | Adjudicated Anaphylaxis | Clinically Relevant Bradycardia | Clinically Relevant Tachycardia | Other Clinically Relevant Cardiac Arrhythmia | Drug Induced Liver Injury | |
| Neostigmine + Glycopyrrolate | 3.9 | 0.0 | 0.0 | 2.0 | 0.0 | 2.0 | 0.0 |
| Sugammadex 16 mg/kg | 7.4 | 0.0 | 0.0 | 0.0 | 5.9 | 1.5 | 0.0 |
| Sugammadex 2 mg/kg | 1.9 | 0.0 | 0.0 | 0.0 | 1.9 | 0.0 | 0.0 |
| Sugammadex 4 mg/kg | 5.6 | 0.0 | 0.0 | 2.8 | 1.9 | 0.9 | 0.0 |
4 reviews available for neostigmine and Tachycardia
| Article | Year |
|---|---|
Use of low-dose neostigmine intravenously in the treatment of thyroid storm-induced severe tachycardia in patient during huge pelvic mass resection: A case report and review of literature.
Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Adult; Cholinesterase Inhibitor | 2018 |
Treatment of cardiac arrhythmias.
Topics: Adams-Stokes Syndrome; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 1964 |
Subacute dysautonomia with incomplete recovery.
Topics: Accommodation, Ocular; Acetylcholine; Adie Syndrome; Adult; Biopsy; Carbachol; Cystoscopy; Dexametha | 1972 |
Management of cardiac dysrhythmias complicating acute myocardial infarction.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atropine; Bradycardia; Bretylium Compound | 1968 |
3 trials available for neostigmine and Tachycardia
| Article | Year |
|---|---|
A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants.
Topics: Aged; Bradycardia; Cholinergic Agents; Double-Blind Method; Female; Glycopyrrolate; Humans; Male; Ne | 2021 |
A comparison of the combination of atropine and glycopyrrolate with atropine alone for the reversal of muscle relaxant.
Topics: Adult; Anesthesia, General; Arrhythmias, Cardiac; Atropine; Cholinesterase Inhibitors; Glycopyrrolat | 2014 |
Less tachycardia in adults when using atropine 0.9 mg compared with 1.2 mg plus neostigmine 2.5 mg.
Topics: Adult; Anti-Arrhythmia Agents; Atropine; Double-Blind Method; Female; Heart Rate; Humans; Male; Neos | 2008 |
24 other studies available for neostigmine and Tachycardia
| Article | Year |
|---|---|
Nodal Tachycardia Induced By Neostigmine Administration During Off-Pump Coronary Artery Bypass Graft Surgery: What Makes the Difference? A Case Report.
Topics: Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Humans; Neostigmine; Tachycardia; Treatmen | 2023 |
Effects of Anticholinesterase Reversal Under General Anesthesia on Postoperative Cardiovascular Complications: A Retrospective Cohort Study.
Topics: Adult; Aged; Anesthesia, General; Boston; Bradycardia; Cholinesterase Inhibitors; Female; Glycopyrro | 2020 |
The action of neostigmine in supraventricular tachycardias.
Topics: Humans; Neostigmine; Tachycardia; Tachycardia, Supraventricular | 1948 |
Right to the heart: a case of accidental phenylephrine intoxication.
Topics: Adult; Cholecystectomy, Laparoscopic; Humans; Hypertension; Injections, Intravenous; Male; Medicatio | 2011 |
Neostigmine bromide orally in prevention of paroxysmal supraventricular tachycardia.
Topics: Biomedical Research; Humans; Neostigmine; Tachycardia; Tachycardia, Paroxysmal; Tachycardia, Suprave | 1952 |
[Protracted treatment of paroxysmal tachycardia with new anticholinesterase preparations].
Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Tachycardia; Tachycardia, Paroxysmal | 1958 |
[Paroxysmal tachycardia in infants].
Topics: Child; Digitalis; Digitalis Glycosides; Humans; Infant; Neostigmine; Plant Extracts; Tachycardia; Ta | 1959 |
TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA IN INFANCY.
Topics: Anti-Bacterial Agents; Digitalis Glycosides; Humans; Infant; Infant, Newborn; Infusions, Parenteral; | 1964 |
[ON CARDIAC RHYTHM CONTROL IN PULMONARY AND PLEURAL SURGERY].
Topics: Cardiac Complexes, Premature; Empyema; Empyema, Tuberculous; Humans; Neostigmine; Pacemaker, Artific | 1964 |
THE PROPER USE OF CAROTID SINUS STIMULATION.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Carotid Sinus; Diagnosis; Digitalis Glycosides; Drug Therapy; | 1964 |
Use of cholinergic drugs in paroxysmal supraventricular tachycardia; serious untoward reactions and fatality from treatment with methacholine and neostigmine.
Topics: Cholinergic Agents; Humans; Methacholine Chloride; Neostigmine; Tachycardia; Tachycardia, Paroxysmal | 1952 |
Cardiac arrest after neuromuscular blockade reversal in a heart transplant infant.
Topics: Biopsy; Cardiac Catheterization; Cardiovascular Abnormalities; Cholinesterase Inhibitors; Graft Reje | 2007 |
Anticholinesterase drugs and the transplanted heart.
Topics: Cholinesterase Inhibitors; Graft Rejection; Heart Arrest; Heart Transplantation; Humans; Infant; Mal | 2008 |
Effect of certain drugs upon amitriptyline induced electrocardiographic changes.
Topics: Acetylcholine; Amitriptyline; Animals; Atropine; Blood Pressure; Bradycardia; Bundle-Branch Block; E | 1966 |
Mechanisms of tachycardia caused by atropine in conscious dogs.
Topics: Acetylcholine; Animals; Atropine; Blood Pressure; Cardiac Output; Dogs; Electric Stimulation; Heart | 1967 |
Anomalous atrio-ventricular connections and their features.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrioventr | 1976 |
Drugs of choice for atrial tachycardia.
Topics: Administration, Oral; Digitalis Glycosides; Digoxin; Edrophonium; Humans; Lanatosides; Metaraminol; | 1975 |
Letter: Neostigmine methysulfate in the treatment of cardiac arryhthmia induced by perphenazine-amitriptyline.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Child, Preschool; Drug Combin | 1976 |
Three therapeutic approaches in tachycardia.
Topics: Atrial Fibrillation; Atrial Flutter; Digitalis Glycosides; Electric Countershock; Heart Conduction S | 1973 |
Glycopyrrolate as a substitute for atropine in neostigmine reversal of muscle relaxant drugs.
Topics: Anesthesia; Atropine; Bradycardia; Curare; Drug Combinations; Female; Glycopyrrolate; Heart Rate; Hu | 1972 |
The effects of atropine and neostigmine on heart rate and rhythm. Recommendation for their use to reverse residual neuromuscular block.
Topics: Adult; Aged; Anesthesia, General; Arrhythmias, Cardiac; Atropine; Benperidol; Female; Fentanyl; Halo | 1971 |
[Prolonged supraventricular ectopic tachycardia in the child. (16 cases)].
Topics: Arrhythmia, Sinus; Child; Child, Preschool; Digoxin; Electrocardiography; Electroconvulsive Therapy; | 1969 |
Aortic valve replacement in the Wolff-Parkinson-White syndrome.
Topics: Adult; Aortic Valve; Heart Valve Prosthesis; Humans; Male; Neostigmine; Postoperative Complications; | 1968 |
A possible role of cholinergic effects in the noradrenaline potentiating action of imipramine.
Topics: Animals; Arrhythmias, Cardiac; Bradycardia; Cats; Dogs; Electrocardiography; Female; Hexamethonium C | 1966 |